Clinical trial • Phase III • Immunology
MK-6050 for Hidradenitis suppurativa
Phase III trial of MK-6050 for Hidradenitis suppurativa. 52 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Hidradenitis suppurativa
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 11-03-2026
- First CTIS Authorization Date
- 13-04-2026
Trial design
Phase III trial across 1 site in Belgium.
- Target Sample Size
- 52
Eligibility
Recruits 52 Vulnerable populations not selected (isVulnerablePopulationSelected=false). No consent/assent handling details provided in the record..
- Vulnerable Population
- Vulnerable populations not selected (isVulnerablePopulationSelected=false). No consent/assent handling details provided in the record.
Recruitment
- Planned Sample Size
- 52
- Recruitment Window Months
- 4
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 52
Belgium
- Earliest CTIS Part Ii Submission Date
- 31-03-2026
- Latest Decision Or Authorization Date
- 13-04-2026
- Processing Time Days
- 13
- Number Of Sites
- 1
- Number Of Participants
- 52
Sites
- Site Name
- SGS Belgium
- Department Name
- SGS Clinical Pharmacology Unit
- Contact Person Name
- Nick Praet
- Contact Person Email
- nick.praet@sgs.com
Sponsor
Primary sponsor
- Full Name
- Merck Sharp & Dohme LLC
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- MK-6050
Related trials
Other published trials that may interest you.